Regardless of size or location, we work with clients all over the world ranging from multinational corporations to lone academics in order to help advance their science.
DiscoveryBioMed’s mission is to fill a critical niche within the drug discovery industry by specializing in custom human cell engineering and human cell-based drug discovery and commercialization. Our R&D infrastructure and know-how are leveraged as a preclinical CRO service to support the commercial and academic drug discovery community by integrating human cell platforms at any and all points within the drug discovery critical path, from HTS assay development and optimization to lead prioritization and progression, with the end product being ‘high value’ clinical candidates.
Academic labs and small biotechs have been adopters of our human cell platforms early in the drug discovery process, whereas large BioPharmas have been more interested in DBM’s capacity to design, develop and implement primary human cell systems for lead prioritization and progression. As an example of our services, DBM routinely performs targeted and phenotypic HTS assay development and primary HTS, custom primary cell culture and/or immortal cell line creation and secondary/tertiary validation and mechanism of action analysis with primary human cell systems.
DBM refers to our novel scientific approach and niche within this marketplace as Humanized Drug Discovery.
If the end goal is to give a drug to a human patient, why not discover new drugs with relevant human cell platforms? The DBM approach to drug discovery is designed to improve the attrition rate and yield high value clinical candidates by introducing disease relevant and physiologically relevant human cell platforms as early as possible in the process.
Discovery Biomed’s scientific expertise has developed over many years of human cell physiology research.
Our laboratory is equipped with a state-of-the-art cell culture and engineering facility. Coupled to that, we have high-throughput molecular screening (HTS) capability with all types of luminescence, fluorescence, and absorbance detection. These facilities provide the means to perform many different high-throughput bioassays on human and mammalian cell-based platforms.
Our compound libraries come from diverse synthetic and natural-product sources. The selection of these libraries is guided by our company’s expertise in physiology and biochemistry. DBM has more than 75,000 small molecules as well as phytochemical extracts available to test on each endpoint, target, pathway or system.
DBM’s philosophy is that the best molecular screening approach to drug discovery is to utilize in vitro cell lines or primary cultures (preferably, human) that are as close to in vivo conditions as possible. Its diseased and wild-type cell lines are engineered to retain phenotypes through many cycles of cell division, leading to reliable results from high throughput cell screening assays. DBM refers to this innovative approach as Humanized Drug Discovery.
In its own discovery work using the same infrastructure as its services business, DBM brings the same expertise, tools, and philosophy to bear on identifying compounds with promise as therapeutics for respiratory, metabolic, and hyperproliferative (renal, urologic, oncologic) human diseases.
Statement Regarding Financial Conflict of Interest for Research Funded Under PHS Grants:
DiscoveryBioMed, Inc takes seriously each potential Conflict of Interest that could affect the integrity of any Public Health Service (PHS)-funded Research performed by its employees and Subrecipients. As a result and in compliance with federal law and regulations, an DBM Investigator shall not participate in any PHS-funded Research if he or she has a Financial Interest that could influence the design, conduct or reporting of such Research activity. DBM will take immediate action under this policy to manage, reduce or eliminate any such Conflict of Interest. As set forth herein, all PHS-funded Research undertaken at DBM shall be conducted in full compliance with this policy and with all applicable federal and state laws pertaining to financial conflicts of interest, including, without limitation, Title 42 Code of Federal Regulations (CFR) Part 50 Subpart F for grants and cooperative agreements and Title 45 CFR Part 94 for Research contracts (collectively, FCOI Regulations). Investigators failing to comply with all FCOI Regulations shall be subject to sanctions, up to and including termination of employment. All underlined terms shall have the meanings as set forth herein.